Additionally, the 36-month beta value for IMRX is -0.34. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 1 rating it as “sell.”
The public float for IMRX is 22.40M and currently, short sellers hold a 10.23% ratio of that float. The average trading volume of IMRX on December 27, 2024 was 1.14M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IMRX) stock’s latest price update
The stock price of Immuneering Corp (NASDAQ: IMRX) has dropped by -3.11 compared to previous close of 2.25. Despite this, the company has seen a gain of 34.57% in its stock price over the last five trading days. globenewswire.com reported 2024-12-19 that – Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer – – Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 – CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board.
IMRX’s Market Performance
IMRX’s stock has risen by 34.57% in the past week, with a monthly rise of 4.81% and a quarterly drop of -16.48%. The volatility ratio for the week is 12.62% while the volatility levels for the last 30 days are 10.65% for Immuneering Corp The simple moving average for the past 20 days is 7.35% for IMRX’s stock, with a 22.24% simple moving average for the past 200 days.
Analysts’ Opinion of IMRX
Needham, on the other hand, stated in their research note that they expect to see IMRX reach a price target of $15, previously predicting the price at $20. The rating they have provided for IMRX stocks is “Buy” according to the report published on March 15th, 2024.
IMRX Trading at 8.37% from the 50-Day Moving Average
After a stumble in the market that brought IMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.47% of loss for the given period.
Volatility was left at 10.65%, however, over the last 30 days, the volatility rate increased by 12.62%, as shares surge +6.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.63% lower at present.
During the last 5 trading sessions, IMRX rose by +34.57%, which changed the moving average for the period of 200-days by -62.77% in comparison to the 20-day moving average, which settled at $2.03. In addition, Immuneering Corp saw -70.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMRX starting from Cormorant Asset Management, LP, who sale 400,000 shares at the price of $2.90 back on Apr 01 ’24. After this action, Cormorant Asset Management, LP now owns 2,895,273 shares of Immuneering Corp, valued at $1,160,181 using the latest closing price.
Schall Thomas J., the Director of Immuneering Corp, purchase 2,900 shares at $2.55 during a trade that took place back on Mar 22 ’24, which means that Schall Thomas J. is holding 2,900 shares at $7,385 based on the most recent closing price.
Stock Fundamentals for IMRX
Current profitability levels for the company are sitting at:
- 0.65 for the present operating margin
- 1.01 for the gross margin
The net margin for Immuneering Corp stands at 0.62. The total capital return value is set at -1.0. Equity return is now at value -71.81, with -63.66 for asset returns.
Currently, EBITDA for the company is -58.06 million with net debt to EBITDA at 0.68. When we switch over and look at the enterprise to sales, we see a ratio of -0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.99.
Conclusion
In conclusion, Immuneering Corp (IMRX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
